Crescent Biopharma (NASDAQ:CBIO) Insider Barbara Harlin Bispham Sells 620 Shares

Crescent Biopharma, Inc. (NASDAQ:CBIO) insider Barbara Bispham sold 620 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $17.90, for a total transaction of $11,098.00. Following the completion of the transaction, the insider owned 18,710 shares of the company’s stock, valued at approximately $334,909. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Barbara Harlin Bispham also recently made the following trade(s):

• On Monday, June 22nd, Barbara Bispham sold 1,218 shares of Crescent Biopharma stock. The shares were sold at an average price of $17.99, for a total transaction of $21,911.82.

Crescent Biopharma Stock Performance

CBIO opened at $16.89 on Friday. The stock has a market cap of $627.29 million, a price-to-earnings ratio of -2.51 and a beta of 1.24. The firm’s fifty day moving average is $17.12 and its 200 day moving average is $17.43. Crescent Biopharma, Inc. has a fifty-two week low of $8.72 and a fifty-two week high of $27.41.

Crescent Biopharma (NASDAQ:CBIO) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.74). On average, equities research analysts predict that Crescent Biopharma, Inc. will post -2.91 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. TD Cowen raised Crescent Biopharma to a “strong-buy” rating in a research note on Monday, August 24th. Wedbush reaffirmed an “outperform” rating and set a $27.00 price objective on shares of Crescent Biopharma in a report on Monday, September 14th. HC Wainwright reiterated a “neutral” rating on shares of Crescent Biopharma in a research report on Thursday, July 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Crescent Biopharma in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $29.60.

Crescent Biopharma News Roundup

Here are the key news stories impacting Crescent Biopharma this week:

• Neutral Sentiment: CEO Joshua Brumm, COO Jonathan McNeill, CFO Richard Scalzo, and other insiders collectively sold 16,726 shares worth approximately $285,501 between September 16 and September 18. The sales reduced individual holdings by roughly 0.5% to 3.2%, but insiders continued to retain meaningful positions. SEC insider transaction filing
• Neutral Sentiment: All reported transactions were executed under pre-arranged Rule 10b5-1 trading plans and were described as sales to cover tax-withholding obligations tied to vested equity awards. That reduces the likelihood that the transactions represent a change in management’s outlook, although the aggregate selling may still weigh modestly on sentiment. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by senior executives—including the CEO and COO—could be viewed as a near-term supply or sentiment overhang. However, the relatively small percentage reductions and tax-related rationale make this a limited negative signal rather than a clear indication of weakening business prospects. SEC insider transaction filing

Institutional Trading of Crescent Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new stake in Crescent Biopharma in the second quarter valued at approximately $38,000. Cannon Global Investment Management LLC acquired a new position in shares of Crescent Biopharma in the 1st quarter valued at $187,000. Persistent Asset Partners Ltd purchased a new stake in Crescent Biopharma in the 2nd quarter valued at $197,000. Wellington Management Group LLP purchased a new stake in Crescent Biopharma in the 2nd quarter valued at $263,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Crescent Biopharma during the 2nd quarter worth $320,000. Institutional investors and hedge funds own 75.19% of the company’s stock.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc (NASDAQ: CBIO) is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company’s activities center on research, preclinical development and clinical evaluation of investigational drug candidates.

Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources.

The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships.